Does Mounjaro Not Work for Some People — and Why?

What the trial data actually show about individual response

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes. At 15mg, average body-weight reduction reached roughly 20–21% over 72 weeks. But an average is a midpoint, not a guarantee, and the trial data show a broad distribution on either side of it. A proportion of participants lost substantially less (some under 5%) while others exceeded 25%. Tirzepatide is the only dual GIP and GLP-1 receptor agonist licensed in the UK for weight management, which means it acts on two gut-hormone pathways simultaneously; that mechanism is genuinely novel, but novelty does not override individual biology.

NICE, in its appraisal of tirzepatide (TA1026), built a formal checkpoint into its recommendations precisely because non-response is a recognised clinical reality: if a patient loses less than 5% of their body weight after six months at the highest tolerated dose, continuing treatment should be reviewed. That is a sensible evidence-based threshold, not a judgement on the person.

So when people ask whether Mounjaro just does not work for some people, the honest answer is: yes, for a minority, the weight-loss response is limited, and that is supported by the published data, not anecdote.

Why some people respond less strongly than others

Several factors appear to reduce or slow response, though the science is still developing. Genetic variation in GIP and GLP-1 receptor expression means the signalling cascade tirzepatide triggers is stronger in some people than others. This is not visible on a blood test or BMI chart, it is an underlying biological difference that even a prescriber cannot predict precisely in advance.

Certain co-existing conditions matter too. People taking Mounjaro alongside treatments that affect appetite, metabolism or gut motility may find those medicines interact with tirzepatide's mechanisms. Hypothyroidism that is under-treated can blunt weight-loss response. Insulin resistance patterns in type 2 diabetes can alter how the body processes the appetite signal tirzepatide generates.

Lifestyle variables play a genuine role as well. Tirzepatide reduces appetite, but it does not eliminate the effect of very high-calorie dietary patterns entirely, nor does it replace the metabolic benefit of physical activity. If the behavioural side of treatment does not shift at all, the medicine's impact is likely to be smaller. That is not blame, it is physiology. And for people who want to understand why they personally are not seeing the results they expected, our page on why Mounjaro may not be working for you specifically goes into this in more depth.

Dose timing and the slow-response trap

One thing that gets missed in discussions about non-response is the titration schedule. Mounjaro starts at 2.5mg, a dose whose job is to let your system adjust, not to produce significant weight loss. Expecting results at 2.5mg that the trials only demonstrated at 10–15mg is setting an unfair benchmark. The prescriber-led escalation typically moves in roughly four-week steps, which means it can take several months before a patient reaches a dose where clinical effect is meaningful.

Timing pressures are real. Some people start treatment in December, hit their first dose increase in January when life is turbulent, and draw conclusions about efficacy before they have actually reached a therapeutic dose. Others order mid-month, miss a week around the school holidays, and inadvertently disrupt the steady-state blood levels that weekly dosing is designed to maintain. Consistency matters more than most people realise when they begin.

If you are in the early stages and feeling uncertain, our full Mounjaro overview explains what each phase of treatment is designed to do. A closer look at weight-loss variation on Mounjaro covers how common a slow start actually is.

What to do if you feel Mounjaro is not working

The first step is to bring it to your prescriber rather than stopping quietly. A clinical review can identify whether the dose is still appropriate, whether concurrent medicines might be reducing absorption or effect, and whether any adjustable lifestyle factors are in play. Stopping abruptly without guidance means losing any progress already made and potentially restarting from scratch later.

It is also worth noting that tirzepatide is not the only licensed weight-management medicine in the UK. For some patients, a different mechanism (such as semaglutide's single GLP-1 pathway via our other available treatments) may produce a better individual response. Prescribers cannot guarantee outcomes, but they can make informed switches. The reasons why Mounjaro can fall short for certain people are varied enough that a one-size conclusion rarely fits.

Cost is a practical factor too. If you are weighing whether to continue, understanding the full picture of current Mounjaro pricing in the UK is useful context, though for a prescription medicine, efficacy and clinical safety remain the primary measures, not the monthly invoice. Our clinical team reviews every case individually, so any concern about response is something a real prescriber reads, not software. That matters when the conversation needs to be nuanced.